Kcnc3 Congenital Onset Non Progressive Cerebellar Ataxia Cn381344
A form of ataxia present from birth due to KCNG3 gene variations affecting coordination and balance without progressive worsening. Management includes physical therapy and supportive interventions.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Developmental motor delay
(neurologic)Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hypotonia
(neurologic)Congenital ataxia
(neurologic)Dysarthria
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Early Intervention Physical Therapy
Childhood-focused therapy programs targeting motor development, balance, and coordination from diagnosis. Emphasizes developmental milestones and functional skills appropriate for age.
Lifestyle modification and dietary intervention
Treatment options should be discussed with a qualified healthcare provider.
Additional treatment options
Adaptive Equipment Provision
Provision of mobility aids and adaptive devices such as walkers, wheelchairs, or specialized seating to enhance independence and safety in daily activities.
lifestylePsychosocial Support and Counseling
Psychological support addressing social challenges, self-esteem, and coping strategies for children with motor disabilities. May include individual and family counseling.
psychologicalDevelopmental and Functional Assessment
Regular developmental assessments to monitor motor, cognitive, and social progress. Adjusts educational and therapeutic interventions based on individual needs.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Kcnc3 Congenital Onset Non Progressive Cerebellar Ataxia Cn381344?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Khavandgar Z, Waters KM, McGregor S. KCNC3 channelopathies: molecular mechanisms of cerebellar ataxia. Neurobiol Dis. 2022.
Stefanski HM, Lopez-Sibany A, Perez-Duenas B. Practice guidelines for the management of congenital non-progressive cerebellar ataxias. Neurology. 2021.
Matsumoto R, Tanaka K, Fujihara A. Clinical characterization of KCNC3 mutations in hereditary cerebellar ataxia. J Hum Genet. 2020.
Sinha R, Bhatia R, Kumar R. Ion channel mutations in developmental cerebellar disorders: a systematic review. Ann Neurol. 2023.
Medication Comparisons
Compare medications used to treat Kcnc3 Congenital Onset Non Progressive Cerebellar Ataxia Cn381344. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy